Protocol Ledger

NCT06985706 · Phase III · RECRUITING

Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns

Interventional Phase III clinical trial protocol NCT06985706 sponsored by Belfast Health and Social Care Trust in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-19 Enrollment: 264 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06985706
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)264 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06985706
Protocol FieldVerified Registry Value
NCT IdentifierNCT06985706
Consolidated Lead SponsorBelfast Health and Social Care Trust
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment264 participants (ESTIMATED)
Registered Start Date2025-05-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06985706
Hospital Research SiteLocationSite Profile
University Hospital of WalesCardiff, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI